Argenti D, Ireland D, Heald D L
Aventis Pharmaceuticals, U.S. Medical Affairs-Clinical Pharmacology and Pharmacokinetics, Parsippany, New Jersey 08807, USA.
J Urol. 2001 May;165(5):1446-51.
We performed a crossover study to determine the relative pharmacokinetic bioavailability and antidiuretic activity of desmopressin in 16 orally hydrated, healthy human subjects.
The investigation included 5 study periods with 1 period used to establish baseline diuresis in the absence of desmopressin and the remaining 4 randomized to a single 0.6 mg. oral dose of desmopressin administered as whole, crushed or chewed tablets, or as an oral solution. Serial plasma samples were collected for 12 hours for desmopressin pharmacokinetic analysis. Pharmacodynamics were assessed by measuring changes in urine volume and osmolality from baseline. Standard bioequivalence metrics were used to compare the pharmacokinetics and pharmacodynamics of crushed and chewed tablets, and oral solution to that of swallowing whole tablets.
The 90% confidence interval analysis of log transformed plasma desmopressin area under the plasma concentration-time curve from time 0 to infinity and maximum plasma drug concentration showed that crushed and chewed tablet treatments were bioequivalent to swallowing whole tablets. The 90% confidence interval analysis for the decrease in urine volume and increase in urine osmolality demonstrated that crushed and chewed tablets, and oral solution treatments were equivalent to whole tablet treatment in the area under curve from time 0 to the last sampling time point and maximum drug effect.
The results of this study imply that desmopressin administered orally as crushed or chewed tablets, or as an oral solution has the same net effect on decreasing urine volume and increasing urine osmolality as swallowing tablets whole.
我们进行了一项交叉研究,以确定去氨加压素在16名口服补液的健康人类受试者中的相对药代动力学生物利用度和抗利尿活性。
该研究包括5个研究阶段,其中1个阶段用于在无去氨加压素的情况下建立基线利尿,其余4个阶段随机给予单次0.6毫克口服去氨加压素,剂型分别为整片、碾碎或咀嚼片,或口服溶液。采集连续12小时的血浆样本用于去氨加压素药代动力学分析。通过测量尿量和渗透压相对于基线的变化来评估药效学。使用标准生物等效性指标比较碾碎片、咀嚼片和口服溶液与整片吞服的药代动力学和药效学。
对0至无穷大时间血浆浓度 - 时间曲线下log转换后的血浆去氨加压素面积和最大血浆药物浓度的90%置信区间分析表明,碾碎片和咀嚼片治疗与整片吞服生物等效。对尿量减少和尿渗透压增加的90%置信区间分析表明,碾碎片、咀嚼片和口服溶液治疗在0至最后采样时间点的曲线下面积和最大药物效应方面与整片吞服等效。
本研究结果表明,口服碾碎片、咀嚼片或口服溶液形式的去氨加压素在减少尿量和增加尿渗透压方面与整片吞服具有相同的净效应。